Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 19, 2025 06:00 ET | Source: Allogenica

Allogenica Secures €2.5 Million Grant to Advance Universal CAR-T Therapy and Strengthen France’s Biotherapy Leadership

Allogenica Secures €2.5 Million Grant to Advance Universal CAR-T Therapy and Strengthen France’s Biotherapy Leadership Allogenica received a €2.5 million grant from the French government's France...
December 12, 2024 18:34 ET | Source: DiCello Levitt LLP

INVESTOR ALERT: Shareholder Class Action Lawsuit Filed Against Kyverna Therapeutics, Inc. (Nasdaq: KYTX); DiCello Levitt LLP Encourages Investors with Losses to Discuss Their Options with Counsel

SAN DIEGO, Dec. 12, 2024 (GLOBE NEWSWIRE) -- A class action lawsuit has been filed on behalf of all persons and entities who purchased or otherwise acquired Kyverna Therapeutics, Inc. (Nasdaq: KYTX)...
July 31, 2024 07:00 ET | Source: Umoja Biopharma, Inc.

Umoja Biopharma Announces FDA Clearance of IND Application for UB-VV111, a CD19 Directed in situ CAR T for Hematologic Malignancies

- UB-VV111 is potentially the first in situ generated CD19 chimeric antigen receptor (CAR)-T cell therapy to be evaluated in humans in the hematology setting - - First patient expected to be dosed by...
July 10, 2024 08:00 ET | Source: Cargo Therapeutics, Inc.

CARGO Therapeutics Announces Phase 1 Clinical Study of Firi-cel CAR T-Cell Therapy Published in The Lancet

CARGO Therapeutics Announces Phase 1 Clinical Study of Firi-cel CAR T-Cell Therapy Published in The Lancet
May 14, 2024 16:05 ET | Source: Cargo Therapeutics, Inc.

CARGO Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

CARGO Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
March 11, 2024 11:39 ET | Source: Imugene Limited

Phase 1 onCARlytics solid tumour trial advances to combination arm treatment

Phase 1 trial of CD19 oncolytic virotherapy drug candidate onCARlytics cleared its first cohort within the intratumoral monotherapy arm of the study.
November 09, 2023 20:07 ET | Source: Cargo Therapeutics, Inc.

CARGO Therapeutics Announces Pricing of Initial Public Offering

CARGO Therapeutics Announce Pricing of IPO
October 01, 2020 08:00 ET | Source: TeneoBio, Inc

Teneobio Announces US FDA Clearance of Investigational New Drug Application for TNB-486 and the Initiation of Phase I Clinical Studies in Patients with B-cell Malignancies

NEWARK, Calif., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Teneobio, Inc. and its affiliate TeneoTwo, Inc. announced today that their investigational new drug application (IND) for TNB-486, a bispecific...
April 25, 2016 08:30 ET | Source: Triumvira Immunologics Inc.

Triumvira to Present Corporate Update at the Bloom Burton & Co. Healthcare Investor Conference

HAMILTON, ON and HACKENSACK, NJ --(Marketwired - April 25, 2016) - Triumvira Immunologics Inc. today announced that its President and Chief Executive Officer Tony Fiorino, MD, PhD, will present a...